All posts by medical

RESEARCH THAT MATTERS: Paying attention to the genetic basis for hearing loss key to improving quality of life – TheChronicleHerald.ca

At 12- or 13-years of age, a good student turns bad. He doesnt seem to listen in class. Hes restless.

The boy in this story is a real one. He grew up in an isolated community on the South Coast of Newfoundland, where the genetic lines run deep through many generations.

Dr. Terry-Lynn Young, a member of the gene dream team at Memorial University in St. Johns, first heard about the lad more than 20 years ago.

He started acting out. A hearing test showed he had trouble hearing low frequency sounds. He had a male teacher, and he simply couldnt hear him well.

It turned out the hearing loss was a genetic legacy and the cause of the sudden onset of his troubles at school.

Young was a postdoctoral fellow and member of the Memorial team that worked with members of the boys family, several of whom wore hearing aids.

Anne Griffin, an audiologist on Youngs team confirmed low-frequency hearing loss in family members. Unfortunately, the hearing aids had been tuned to amplify high-pitched sounds.

The audiologist adjusted the aids, cranking up the volume of low frequency sounds. Grown men came out of her office with tears in their eyes. They could finally hear, says Young, a leading geneticist who spent her formative years in St. Anthony, at the top of Newfoundlands Great Northern Peninsula.

The Memorial team conducted genetic testing, finally finding the gene that had impacted the familys hearing for eight generations.

In 2001, Young and others published the results in Human Molecular Genetics, a journal published by Oxford University Press. Almost two decades later, she is incredibly frustrated that the key insight of that peer-review article has not made its way widely into clinical practice.

The insight was that a patients genetics should form the basis of care for hearing loss from each according to his genome, to each according to his needs.

Care for hearing loss, based on genetic testing, is not complicated as it sounds, either. In some cases, audiologists can simply fine tune hearing devices the same way you do your stereo turn down the bass, turn up the treble, and deliver more sound to the right speaker if required.

But the genetic understanding of hearing loss now goes deeper than that, Dr. Young said.

We can tell if the hearing loss is in one ear or both ears, if it gets worse or stays the same over time, if it is high frequency or low frequency loss, if it is likely to impact people when they are older or younger. Its like we know each and every cell.

The underlying health care issue is urgent. Hearing loss is the most common sensory disorder of all in humans, she says, and is now linked to social isolation, dementia in older people, and learning problems in children.

Young describes the cochlea - the snail shaped portion of the inner ear that converts sound vibrations into nerve impulses to the brain as elegant and beautiful. Its a triumph of genetics that the cochlear system is so well-understood. Its a failure of health care delivery that this understanding isnt better reflected in clinical practice.

A good start at improving care delivery would be easier public access to genetic testing, which can be done from a single strand of hair or saliva sample just like on a TV cop show. How do we roll out genetic testing at Costco?, Young asked.

Another step forward would be better training in genetics for student audiologists. Thats sorely lacking today. As a result, audiologists use standard hearing tests, which often fall short of what is needed and as the family from the South Coast of Newfoundland learned the hard way.

As part of Memorials team of geneticists, Young knows that genetic breakthroughs can sometimes result in better patient care in a hurry.

She and her colleagues identified a genetic anomaly in a Newfoundland family that caused sudden cardiac arrest and often early death especially among males. Your first symptom could be your last, she said.

Cardiologists implanted defibrillators in these patients - to restart the heart in case of an incident before Youngs team found the underlying gene.

That was brilliant, she said. The caregivers were out in front of the genetic knowledge, not trailing it.

Young is determined to see genetics play a more significant role in treating hearing care as well.

Im going to beat this drum loud enough that everyone hears she said.

Research That Matters is written by Jim Meek, Public Affairs Atlantic, on behalf of the Association of Atlantic Universities (AAU).

RELATED:

More here:
RESEARCH THAT MATTERS: Paying attention to the genetic basis for hearing loss key to improving quality of life - TheChronicleHerald.ca

Study Probes Interaction of Genetics and Neural Wiring in ADHD – PsychCentral.com

A new study comparing genetics and the neural wiring of the brain suggests a diagnosis of attention-deficit/hyperactivity disorder (ADHD) results from a combination of factors. Investigators discovered that it takes many common genetic variations combining together in one individual to increase risk substantially.

At the same time, neuroimaging (MRI) experts have found differences in how the brains of people diagnosed with ADHD are functionally connected. However, its unclear how genetic risk might be directly related to altered brain circuitry in individuals diagnosed with ADHD.

In the new study, researchers focused their imaging analyses on selected brain regions, looking specifically at the communication between those regions and the rest of the brain in children with the diagnosis.

They discovered that one brain regions connectivity was linked to a higher risk of ADHD. However, a second, different part of the brain seemed to compensate for genetic effects and reduce the chances of an ADHD diagnosis.

The authors believe this research will lead to a better understanding of how genetic risk factors alter different parts of the brain to change behaviors and why some people at higher genetic risk do not exhibit ADHD symptoms.

The study appears in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.

We are now in a phase with enough data to answer some questions about the underlying genetics of a disorder that in the past have been difficult to elucidate, said senior author Damien Fair, Ph.D.

Previous imaging studies had shown different functional connectivity, and we assume those have a genetic basis.

ADHD is a neurodevelopmental psychiatric disorder that affects about 5 percent of children and adolescents and 2.5 percent of adults worldwide. The disorder is characterized by inattentive or hyperactive symptoms with many variations.

The paper focuses on 315 children between the ages of 8 and 12 who participated in a longitudinal ADHD study that began in 2008 at the Oregon Health & Science University in Portland. Fair, a neuroscientist and imaging researcher, and co-author Joel Nigg, Ph.D., a pediatric psychologist participated in the study. Robert Hermosillo, Ph.D., a postdoctoral researcher in Fairs lab, led the study.

The research team selected three areas of the brain based on a brain tissue database that showed where ADHD risk genes were likely to alter brain activity. To measure the brain communication to-and-from these regions on each side of the brain, the researchers used resting-state non-invasive magnetic resonance imaging (MRI) scans.

To begin to bridge genetic and neuroimaging studies of ADHD, researchers used MRI to scan the brains of children. Two regions previously associated with ADHD stood out. In one, a higher ADHD genetic risk correlated with a more active brain circuit anchored by the nucleus accumbens (orange arrow). Interestingly a weaker connection anchored by the caudate nucleus (blue arrow) seemed to protect children at high genetic risk from ADHD behaviors.

Next, they calculated a cumulative ADHD genetic risk score in the children, based on recent genome-wide studies, including a dozen higher-risk genetic regions reported two years ago by a large international collaboration called the Psychiatric Genetics Consortium.

In one brain region anchored by the nucleus accumbens, they found a direct correlation with genetics. Increased genetic risk means stronger communication between the visual areas and the reward centers, explained Hermosillo.

Another brain region anchored by the caudate yielded more puzzling results until the researchers tested its role as a mediator between genetics and behavior.

The less these two regions talk to each other, the higher the genetic risk for ADHD, said Hermosillo. It seems to provide a certain resiliency against the genetic effects of ADHD. Even among those with high risk for ADHD, if these two brain regions are communicating very little, a child is unlikely to end up with that diagnosis.

A third region, the amygdala, showed no correlation between connectivity to the other brain regions and the genetics.

According to the authors, the findings suggest that a genetic score alone will not be enough to predict ADHD risk in individuals because the results show both a genetic and neural contribution toward an ADHD diagnosis.

A future diagnostic tool will likely need to combine genetics and brain functional measures. The brain is not at the mercy of genes, added Hermosillo. Its a dynamic system not preprogrammed for disorders. It has the capacity to change.

Source: Elsevier

Related Articles

Visit link:
Study Probes Interaction of Genetics and Neural Wiring in ADHD - PsychCentral.com

Yann Joly on the fight against genetic discrimination – McGill Reporter

Yann Joly, Research Director of the Centre of Genomics and Policy

Research Director of the Centre of Genomics and Policy and Associate Professor at the Department of Human Genetics, Yann Joly is a Lawyer Emeritus from the Quebec Bar and a Fellow of the Canadian Academy of Health Sciences. He is currently a member of the Quebec task force on theCOVID-19 Biobank.

Last week, Joly and his collaborators from 16 countries announced the establishment of the international Genetic Discrimination Observatory (GDO). A world first, the GDO is an online platform committed to preventing the misuse of a patients genetic information. This is particularly important within the current context of the COVID-19 pandemic when researchers are collecting samples and data from patients in order to better understand this new disease and develop effective vaccines or therapeutics.

In this Q&A, Joly gives readers more information on genetic discrimination and what is being done to combat it.

Genetic discrimination (GD) means treating people differently from the rest of the population or unfairly profiling them based on actual or presumed genomic and other predictive medical data. The genetic information contained in an individuals DNA can uniquely identify or provide some information about a person, including future probabilities that this individual will develop diseases. Other predictive health information, such as biomarkers, can also be used to discriminate and should also be considered under the GD heading.

This information can be of interest to third parties like insurers, employers, or government officials. Like sexual, ethnic or disability-based discrimination, genetic discrimination is a source of exclusion and can limit the social and professional opportunities of a person thus becoming a source of psychological distress.

There are documented cases of GD reported in studies carried out in a limited number of countries based on predictive test results and family history for a handful of severe single-gene conditions in the context of life insurance or employment. The available evidence is fragmentary, and the methodology used in many studies is inconsistent.

The Genetic Non-Discrimination Act (hereinafter S-201) was passed in April 2017 and is currently applicable in Canada. While it does not solve all the challenges posed by genetic discrimination, it is an important first step. The Act generally makes it a criminal offense to require a person to undergo a genetic test or to report the results as a condition precedent to the provision of goods and services. However, the Quebec Court of Appeal recently declared that the core elements of S-201 were not constitutionally valid.

This decision was appealed to the Supreme Court of Canada and we are currently waiting for their decision on the matter. In the meantime, S-201 continue to be applied. If the Supreme Court is of a similar opinion to that of the Court of Appeal, it could be invalidated.

In addition to the protection provided by S-201, Canadian privacy laws would fully apply to genetic data, which is considered personal information.

Genetic information is increasingly shared across national borders or transcending them, thus limiting the effectiveness of protections built solely around national approaches. Strictly legal solutions, because they tend to be static, are also challenged to keep pace with rapidly evolving science such as genetics.

At its core discrimination is a social phenomenon that needs to be addressed collaboratively and internationally by all stakeholders. The GDO will provide the platform to undertake this important work, which will include documenting instances of genetic discrimination, identifying most effective preventing measures and conveying information, tools and good practices to all stakeholders including the public.

COVID-19 presents Quebecers with an unprecedented health threat that requires us to stand together as a society and take action to protect one another and help find medical solutions to the disease. The COVID-19 Biobank provides us a unique opportunity to learn more about the biological foundations of the disease, individuals at risk and preventive solutions.

The risk of discrimination associated with providing a biological sample and medical information to the Biobank is very small. The data provided is research information that is not clinically validated and should be of no interest to most third parties. Moreover, the collected information is coded, and protected by confidentiality laws and robust security measures. Furthermore, data access will be subject to ethics approval and in some cases controlled access measures.

See the rest here:
Yann Joly on the fight against genetic discrimination - McGill Reporter

Seattle Genetics Announces Potential Accelerated Approval Pathway in the US for PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy…

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc.. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEVTM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Based on recent discussions with the U.S. Food and Drug Administration (FDA), data from the randomized cohort K, along with other data from the EV-103 trial evaluating PADCEV combined with pembrolizumab as first-line therapy for cisplatin-ineligible patients, could potentially support registration under accelerated approval regulations in the United States. PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1

We are excited that EV-103 provides PADCEV with a potential pathway for U.S. accelerated approval in first-line metastatic urothelial cancer, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.

EV-103 is a multi-cohort, open-label, multicenter phase 1b/2 trial of PADCEV alone or in combination, evaluating safety, tolerability and efficacy in muscle invasive urothelial cancer, and in locally advanced or metastatic urothelial cancer in first- or second-line settings. Cohort K from EV-103 is intended to enroll 150 patients randomized 1:1 to PADCEV monotherapy or PADCEV in combination with pembrolizumab in locally advanced or metastatic urothelial cancer patients who are ineligible for cisplatin-based chemotherapy. The primary outcome measure is objective response rate (ORR) per blinded independent central review (BICR) using RECIST 1.1 and duration of response (DoR).

In addition to EV-103, the recently initiated EV-302 phase 3 randomized clinical trial is intended to support global registrations and potentially serve as a confirmatory trial if accelerated approval is granted based on EV-103. The EV-302 trial is evaluating the combination of PADCEV and pembrolizumab with or without chemotherapy versus chemotherapy alone in patients with previously untreated locally advanced or metastatic urothelial cancer. Importantly, EV-302 includes metastatic urothelial cancer patients that are either eligible or ineligible for cisplatin-based chemotherapy. The trial is expected to enroll 1,095 patients and has dual primary endpoints of progression-free survival and overall survival. Both the EV-103 and EV-302 trials are being conducted in collaboration with Astellas and Merck.

FDA recently granted Breakthrough Therapy designation for PADCEV in combination with pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting based on initial results from the EV-103 trial.

PADCEV (enfortumab vedotin-ejfv) was approved by the FDA in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV was approved under the FDAs Accelerated Approval Program based on tumor response rate. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.2

About Bladder and Urothelial Cancer

It is estimated that approximately 81,000 people in the U.S. will be diagnosed with bladder cancer in 2020.3 Urothelial cancer accounts for 90 percent of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.4 Globally, approximately 549,000 people were diagnosed with bladder cancer in 2018, and there were approximately 200,000 deaths worldwide.5

About PADCEV

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.6,7 Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).8 PADCEV is co-developed by Astellas and Seattle Genetics.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Serious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade 3 adverse reactions (5%) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab Abnormalities

In one clinical trial, Grade 3-4 laboratory abnormalities reported in 5% were: lymphocytes decreased, hemoglobin decreased, phosphate decreased, lipase increased, sodium decreased, glucose increased, urate increased, neutrophils decreased.

Drug Interactions

Specific Populations

For more information, please see the full Prescribing Information for PADCEV here.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in peoples lives. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit https://www.seattlegenetics.com and follow @SeattleGenetics on Twitter. For information on our response to the COVID-19 pandemic, please visit our website.

About the Astellas and Seattle Genetics Collaboration

Seattle Genetics and Astellas are co-developing PADCEV under a collaboration that was entered into in 2007 and expanded in 2009. Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide.

About the Seattle Genetics, Astellas and Merck Collaboration

Seattle Genetics and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seattle Genetics and Astellas PADCEV and Mercks KEYTRUDA (pembrolizumab), in patients with previously untreated metastatic urothelial cancer. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Seattle Genetics Forward-Looking Statements

Certain statements made in this press release are forward looking, such as those, among others, relating to the potential of data from the EV-103 clinical trial to support accelerated approval in the U.S. of PADCEV in combination with pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting; the possibility of using data from the EV-302 clinical trial to obtain global regulatory approval or confirm accelerated approval of PADCEV in the referenced first line setting; clinical development plans relating to PADCEV; the therapeutic potential of PADCEV; and its possible safety, efficacy, and therapeutic uses, including in the first-line setting. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the possibility that ongoing and subsequent clinical trials of PADCEV may fail to produce data sufficient to support regulatory approvals; the fact that FDA has not made a final determination regarding whether the data from the EV-103 clinical trial will be sufficient to support accelerated approval in the U.S.; the risk that the COVID-19 pandemic could delay our ability to conduct the EV-103 clinical trial and delay FDAs regulatory timelines, including with respect to any potential accelerated approval; the fact that adverse events or safety signals may occur and that adverse regulatory actions or other setbacks could occur as PADCEV advances in clinical trials even after promising results in earlier clinical trials. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

1Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.2 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.3 American Cancer Society. Cancer Facts & Figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed 02-20-2020.4 American Society of Clinical Oncology. Bladder cancer: introduction (10-2017). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed 05-09-2019.5 International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow.6 Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.7 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.8 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005249/en/

Read the original:
Seattle Genetics Announces Potential Accelerated Approval Pathway in the US for PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy...

Her genetic test revealed a microscopic problem and a jumbo price tag – Rome News-Tribune

Michelle Kuppersmith, 32, feels great, works full time and exercises three to four times a week. So she was surprised when a routine blood test found that her body was making too many platelets, which help control bleeding. Kuppersmiths doctor suspected she had a rare blood disorder called essential thrombocythemia, which can lead to blood clots, strokes and, in rare cases, leukemia.

Her doctor suggested a bone marrow biopsy, in which a large needle is used to suck out a sample of the spongy tissue at the center of the patients hip bone. Doctors examine the bone marrow under a microscope and analyze the DNA. The procedure allows doctors to judge a patients prognosis and select treatment, if needed. Kuppersmith had heard the procedure can be intensely painful, so she put it off for months.

The biopsy performed by a provider in her insurance network, at a hospital in her network lasted only a few minutes, and Kuppersmith received relatively good news. While a genetic analysis of her bone marrow confirmed her doctors suspicions, it showed that the only treatment she needs, for now, is a daily, low-dose aspirin. She will check in with her doctor every three to four months to make sure the disease isnt getting worse.

All in all, Kuppersmith felt relieved.

Then she got a notice saying her insurer refused to pay for the genetic analysis, leaving her responsible for a $2,400 payment.

The Patient: New York resident Michelle Kuppersmith, 32, who is insured by Maryland-based CareFirst Blue Cross Blue Shield. She works as director of special projects at a Washington-based, nonpartisan watchdog group. Because she was treated in New York, Empire Blue Cross Blue Shield which covers that region handled part of her claim.

Total Amount Owed: $2,400 for out-of-network genetic profiling

The Providers: Kuppersmith had her bone marrow removed at the Mount Sinai Ruttenberg Treatment Center in New York City, which sent her biopsy sample to a California lab, Genoptix, for testing.

Medical Services: Bone marrow biopsy and molecular profiling, which involves looking for genetic mutations

What Gives: The field of molecular diagnostics, which includes a variety of gene-based testing, is undergoing explosive growth, said Gillian Hooker, president of the National Society of Genetic Counselors and vice president of clinical development for Concert Genetics, a health IT company in Nashville, Tennessee.

A Concert Genetics report found there are more than 140,000 molecular diagnostic products on the market, with 10 to 15 added each day.

The field is growing so quickly that even doctors are struggling to develop a common vocabulary, Hooker said.

Kuppersmith underwent a type of testing known as molecular profiling, which looks for DNA biomarkers to predict whether patients will benefit from new, targeted therapies. These mutations arent inherited; they develop over the course of a patients life, Hooker said.

Medicare spending on molecular diagnostics more than doubled from 2016 to 2018, increasing from $493 million to $1.1 billion, according to Laboratory Economics, a lab industry newsletter.

Charges range from hundreds to thousands of dollars, depending on how many genes are involved and which billing codes insurers use, Hooker said.

Based on Medicare data, at least 1,500 independent labs perform molecular testing, along with more than 500 hospital-based labs, said Jondavid Klipp, the newsletters publisher.

In a fast-evolving field with lots of money at stake, tests that a doctor or lab may regard as state-of-the-art an insurer might view as experimental.

Worse still, many of the commercial labs that perform the novel tests are out-of-network, as was Genoptix.

Stephanie Bywater, chief compliance officer at NeoGenomics Laboratories, which owns Genoptix, said that insurance policies governing approval have not kept up with the rapid pace of scientific advances. Kuppersmiths doctor ordered a test that has been available since 2014 and was updated in 2017, Bywater said.

Although experts agree that molecular diagnostics is an essential part of care for patients like Kuppersmith, doctors and insurance companies may not agree on which specific test is best, said Dr. Gwen Nichols, chief medical officer of the Leukemia & Lymphoma Society.

Tests can be performed a number of different ways by a number of different laboratories who charge different amounts, Nichols said.

Insurance plans are much more likely to refuse to pay for molecular diagnostics than other lab tests. Laboratory Economics found Medicare contractors denied almost half of all molecular diagnostics claims over the past five years, compared with 5-10% of routine lab tests.

With so many insurance plans, so many new tests and so many new companies, it is difficult for a doctor to know which labs are in a patients network and which specific tests are covered, Nichols said.

Different providers have contracts with different diagnostic companies, which can affect a patients out-of-pocket costs, Nichols said. It is incredibly complex and really difficult to determine the best, least expensive path.

Kuppersmith said she has always been careful to check that her doctors accept her insurance. She made sure Mount Sinai was in her insurance network, too. But it never occurred to her that the biopsy would be sent to an outside lab ? or that it would undergo genetic analysis.

She added: The looming threat of a $2,400 bill has caused me, in many ways, more anxiety than the illness ever has.

The Resolution: Despite making dozens of phone calls, Kuppersmith got nothing but confusing and contradictory answers when she tried to sort out the unexpected charge.

An agent for her insurer told her that her doctor hadnt gotten preauthorization for the testing. But in an email to Kuppersmith, a Genoptix employee told her the insurance company had denied the claim because molecular profiling was viewed as experimental.

A spokesperson for New York-based Empire Blue Cross Blue Shield, which handled part of Kuppersmiths claim, said her health plan covers medically necessary genetic testing.

New York, one of 28 states with laws against surprise billing, requires hospitals to inform patients in writing if their care may include out-of-network providers, said attorney Elisabeth Benjamin, vice president of health initiatives at the Community Service Society, which provides free help with insurance problems.

A spokesperson for Mount Sinai said the hospital complies with that law, noting that Kuppersmith was given such a document in 2018 nearly one year before her bone marrow biopsy and signed it.

Benjamin said thats not OK, explaining: I think a 1-year-old, vague form like the one she signed would not comply with the state law and certainly not the spirit of it.

Instead of sending Kuppersmith a bill, Genoptix offered to help her appeal the denied coverage to CareFirst. At first, Genoptix asked Kuppersmith to designate the company as her personal health care representative. She was uncomfortable signing over what sounded like sweeping legal rights to strangers. Instead, she wrote an email granting the company permission to negotiate on her behalf. It was sufficient.

A few days after being contacted by KHN, Kuppersmiths insurer said it would pay Genoptix at the in-network rate, covering $1,200 of the $2,400 charge. Genoptix said it has no plans to bill Kuppersmith for the other half of the charge.

The Takeaway: Kuppersmith is relieved her insurer changed its mind about her bill. But, she said: Im a relatively young, savvy person with a college degree. There are a lot of people who dont have the time or wherewithal to do this kind of fighting.

Patients should ask their health care providers if any outside contractors will be involved in their care, including pathologists, anesthesiologists, clinical labs or radiologists, experts said. And check if those involved are in-network.

Try your best to ask in advance, said Jack Hoadley, a research professor emeritus at Georgetown University. Ask, Do I have a choice about where (a blood or tissue sample) is sent?

Ask, too, if the sample will undergo molecular diagnostics. Since the testing is still relatively new and expensive ? most insurers require patients to obtain prior authorization, or special permission, said Dr. Debra Regier, a medical geneticist at Childrens National Hospital in Washington and an associate with NORD, the National Organization of Rare Diseases. Getting this permission in advance can prevent many headaches.

Finally, be wary of signing blanket consent forms telling you that some components of your care may be out-of-network. Tell your provider that you want to be informed on a case-by-case basis when an out-of-network provider is involved and to consent to their participation.

2020 Kaiser Health News

Visit Kaiser Health News at http://www.khn.org

Distributed by Tribune Content Agency, LLC.

PHOTO (for help with images, contact 312-222-4194)

Read more from the original source:
Her genetic test revealed a microscopic problem and a jumbo price tag - Rome News-Tribune

Social distancing works just ask lobsters, ants and vampire bats – Thehour.com

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Dana Hawley, Virginia Tech and Julia Buck, University of North Carolina Wilmington

(THE CONVERSATION) Social distancing to combat COVID-19 is profoundly impacting society, leaving many people wondering whether it will actually work. As disease ecologists, we know that nature has an answer.

Animals as diverse as monkeys, lobsters, insects and birds can detect and avoid sick members of their species. Why have so many types of animals evolved such sophisticated behaviors in response to disease? Because social distancing helps them survive.

In evolutionary terms, animals that effectively socially distance during an outbreak improve their chances of staying healthy and going on to produce more offspring, which also will socially distance when confronted with disease.

We study the diverse ways in which animals use behaviors to avoid infection, and why behaviors matter for disease spread. While animals have evolved a variety of behaviors that limit infection, the ubiquity of social distancing in group-living animals tells us that this strategy has been favored again and again in animals faced with high risk of contagious disease.

What can we learn about social distancing from other animals, and how are their actions like and unlike what humans are doing now?

Feed the sick, but protect the queen

Social insects are some of the most extreme practitioners of social distancing in nature. Many types of ants live in tight quarters with hundreds or even thousands of close relatives. Much like our day care centers, college dormitories and nursing homes, these colonies can create optimal conditions for spreading contagious diseases.

In response to this risk, ants have evolved the ability to socially distance. When a contagious disease sweeps through their society, both sick and healthy ants rapidly change their behavior in ways that slow disease transmission. Sick ants self-isolate, and healthy ants reduce their interaction with other ants when disease is present in the colony.

Healthy ants even close rank around the most vulnerable colony members the queens and nurses by keeping them isolated from the foragers that are most likely to introduce germs from outside. Overall, these measures are highly effective at limiting disease spread and keeping colony members alive.

Many other types of animals also choose exactly who to socially distance from, and conversely, when to put themselves at risk. For example, mandrills a type of monkey continue to care for sick family members even as they actively avoid sick individuals to whom they are not related. In an evolutionary sense, caring for a sick family member may allow an animal to pass on its genes through that family members offspring.

Further, some animals maintain essential social interactions in the face of sickness while foregoing less critical ones. For example, vampire bats continue to provide food for their sick groupmates, but avoid grooming them. This minimizes contagion risk while still preserving forms of social support that are most essential to keeping sick family members alive, such as food sharing.

These nuanced forms of social distancing minimize costs of disease while maintaining the benefits of social living. It should come as no surprise that evolution favors them in many types of animals.

Altruism makes us human

Human behavior in the presence of disease also bears the signature of evolution. This indicates that our hominid ancestors faced many of the same pressures from contagious disease that we are facing today.

Like social ants, we are protecting the most vulnerable members of our society from COVID-19 infection by ensuring that older individuals and those with pre-existing conditions stay away from potentially contagious people. Like monkeys and bats, we also practice nuanced social distancing, reducing non-essential social contacts while still providing essential care for sick family members.

There also are important differences. For example, in addition to caring for sick family members, humans sometimes increase their own risk by caring for unrelated individuals, such as friends and neighbors. And health care workers go further, actively seeking out and helping precisely those who many of us carefully avoid.

Altruism isnt the only behavior that distinguishes human response to disease outbreaks. Other animals must rely on subtle cues to detect illness among group members, but we have cutting-edge technologies that make it possible to detect pathogens rapidly and then isolate and treat sick individuals. And humans can communicate health threats globally in an instant, which allows us to proactively institute behaviors that mitigate disease. Thats a huge evolutionary advantage.

Finally, thanks to virtual platforms, humans can maintain social connections without direct physical contact. This means that unlike other animals, we can practice physical rather than social distancing, which lets us preserve some of the important benefits of group living while minimizing disease risk.

Worth the disruption

The evidence from nature is clear: Social distancing is an effective tool for reducing disease spread. It is also a tool that can be implemented more rapidly and more universally than almost any other. Unlike vaccination and medication, behavioral changes dont require development or testing.

However, social distancing can also incur significant and sometimes unsustainable costs. Some highly social animals, like banded mongooses, do not avoid group members even when they are visibly sick; the evolutionary costs of social distancing from their relatives may simply be too high. As we are currently experiencing, social distancing also imposes severe costs of many kinds in human societies, and these costs are often borne disproportionately by the most vulnerable people.

Given that social distancing can be costly, why do so many animals do it? In short, because behaviors that protect us from disease ultimately allow us to enjoy social living a lifestyle that offers myriad benefits, but also carries risks. By implementing social distancing when its necessary, humans and other animals can continue to reap the diverse benefits of social living in the long term, while minimizing the costs of potentially deadly diseases when they arise.

Social distancing can be profoundly disruptive to our society, but it can also stop a disease outbreak in its tracks. Just ask ants.

[You need to understand the coronavirus pandemic, and we can help. Read The Conversations newsletter.]

This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/social-distancing-works-just-ask-lobsters-ants-and-vampire-bats-135383.

Read more:
Social distancing works just ask lobsters, ants and vampire bats - Thehour.com

N. Texas doctors developed guidelines to determine what to do if there is a shortage of ventilators – The Dallas Morning News

As physicians, we are constantly asked by both laypeople and health care professionals about the COVID-19 pandemic. Fear is in the air, especially when we are asked who will receive intensive care services if demand exceeds supply.

People express rational fears about treatment for differently enabled, minority, elderly and all other socially disadvantaged communities routinely subjected to discrimination in our society. Our society does not distribute health care resources equitably in ordinary times, and our own lieutenant governor recently implied it might just be better for the elderly to die.

After the 2003-04 SARS epidemic, medical, civic and governmental groups across the country asked: What if SARS or the 1918 Spanish flu happened now, and we didnt have the capacity to provide hospital or intensive care support for every person who might seek it?

In response, the Dallas County Medical Society created the North Texas Mass Critical Care Council. Through the hard work and wisdom of many medical and civic leaders from four counties (Dallas, Tarrant, Collin and Denton), the council created guidelines for a time when demand exceeds supply. We explored not only issues of clinical science, but culture, faith and ethical issues like personal autonomy, responsibility and distributive justice. The guidelines were then translated into hospital and health care system guidelines with two purposes: To save as many lives as possible and to prohibit discrimination in delivery of services.

For example, here is the anti-discrimination statement from the Baylor Scott & White Hospital version of the guidelines: Each patient will receive respect, care, and compassion without regard to basis of race, ethnicity, color, national origin, religion, sex, disability, veteran status, age, genetic information, sexual orientation, gender identity or any other protected characteristic under applicable law.

During a time of overwhelming demand for hospital services, access to treatment would be based upon the patients ability to benefit from it, using objective physiologic criteria. Doctors would rely on the sequential organ failure assessment score, or the SOFA score.

SOFA scoring is an international assessment standard, calculated using objective measurements of things like lung, heart, liver and kidney function. Medical factors, rather than social criteria, guide the physicians judgment about which patients are most likely to benefit from ICU interventions when there are not enough ICU services for every patient. This saves as many lives as possible.

Based on SOFA scores, doctors might determine that an elderly patient with a mild case of COVID-19 is more likely to recover using a hospital ventilator than a young patient whose organs have been overwhelmed by the virus, or vice versa, but the decision would be based entirely on whether the treatment is likely to help the patient recover.

Doctors are prohibited from considering social status, money or other nonmedical criteria when determining how to care for patients. We dont get special access because we are physicians, nor does the chief executive of any hospital, nor does any mayor or county commissioner.

The county medical societies and hospitals in North Texas have all pledged to follow these regional guidelines. We hope and pray we will not need to activate the full guidelines, but we are worried that the time will come, and thus our desire for our entire North Texas community to understand the guidelines in advance.

There are some who say doctors shouldnt make any choice about resource allocation, but simply practice first-come-first-served medicine. That is an approach we considered, but the best evidence we have indicates more lives would be lost and more discrimination would occur. In health care, we see both the best and the worst of human behaviors. We believe that following communitywide guidelines is the best defense we can offer against the worst of human behavior, not only to disadvantaged communities, but to every member of our community.

During ordinary times, but especially during hard times, goodness in the world is not solely dependent on the acts of leaders. Goodness in the world also depends upon individual acts of everyday kindness, compassion and love of ones fellow human beings.

Goodness in the world is dependent upon each of us seeing ourselves as part of a larger community attempting to serve and save as many people as possible. Goodness in the world is dependent upon all of us working together.

Dr. Robert Fine is co-chair of the North Texas Mass Critical Care Council. Dr. Mark Casanova is president of the Dallas County Medical Society. Dr. John Carlo is co-chair of the North Texas Mass Critical Care Council. They wrote this column for The Dallas Morning News.

See more here:
N. Texas doctors developed guidelines to determine what to do if there is a shortage of ventilators - The Dallas Morning News

Star Parker: Free people take responsibility and solve problems – Kankakee Daily Journal

Several months ago, before anyone imagined the current crisis, I read a book called Mans Search for Meaning by Viktor Frankl.

Frankl was a Jewish Viennese psychiatrist who was captured by the Nazis during World War II and managed to survive four concentration camps, including the infamous Auschwitz and Dachau.

He went through the ordeal observing human behavior, and the result was his formulation of a system of therapy he called logotherapy.

Frankl found those who were most successful, surviving under the most challenging circumstances, were those who retained a sense of meaning in their lives. That is, the real challenge every person faces is not whats happening outside of themselves but whats happening inside.

In Frankls own words: Everything can be taken from a man but one thing: the last of human freedoms to choose ones attitude in any given set of circumstances, to choose ones own way.

He continued: Freedom is but the negative aspect of the whole phenomenon whose positive aspect is responsibleness. In fact, freedom is in danger of degenerating into mere arbitrariness unless it is lived in terms of responsibleness.

With all our talk about freedom, somehow its essence has gotten lost: human beings taking responsibility for their own life and the world around them. Human beings are causes, not results. They are free agents, not victims.

I cant think of a more important message as we face these great challenges today as a nation and as individuals.

The whole idea of America was, and hopefully still is, freedom, which means America must be about individuals taking responsibility.

The country now faces two huge areas of uncertainty and lack of clarity.

One is regarding the nature of the health threat we are dealing with. I still am reading different opinions from knowledgeable sources about how lethal this virus is and the best way to stop it without totally shutting down and destroying our economy.

Second, were suffering great absence of clarity in government regarding who is responsible for what.

Times of uncertainty are times, in the spirit of Viktor Frankl, for individuals to step up and take responsibility.

But, unfortunately, were getting the opposite.

Its obscene House Speaker Nancy Pelosi, who held up the emergency stimulus bill to insert left-wing nonsense, accused President Donald Trump of fiddling while people are dying.

Michigan Gov. Gretchen Whitmer complained to the press, Were not getting what we need from the federal government.

But this isnt new. Back in February, Whitmer delivered the Democrats response to President Trumps State of the Union address and went on for her full 10 minutes about the federal government not doing enough.

She touted her efforts to expand health coverage under the Affordable Care Act, meaning more bureaucratization of our hospitals and health care delivery, and creation of government health care incapable of flexibility to changing market realities, let alone dealing with a crisis.

New York Mayor Bill de Blasio is taking deserved heat for his delayed action in response to the crisis in his city. Weeks ago, he was on television talking about how this crisis only could be addressed by the federal government.

This is all the result of generations degrading the clear constitutional lines between the federal government and the states, resulting in massive growth of the welfare state.

As Democratic governors and mayors and Speaker Pelosi use valuable time looking for who to blame, Americas private business already is churning to develop better and faster testing procedures, and soon we will see a drug to eradicate COVID-19.

Small and large businesses are deploying resources in new and creative ways that will pay great dividends when we emerge from this crisis.

Challenges are met by free, responsible people stepping into the void: exactly what Viktor Frankl was talking about.

Star Parker is president of the Center for Urban Renewal and Education and author of the new book Necessary Noise: How Donald Trump Inflames the Culture War and Why This is Good News for America, available now on Amazon.com.

View post:
Star Parker: Free people take responsibility and solve problems - Kankakee Daily Journal

Are We Already Missing the Next Epidemic? – POLITICO

Ive built true-to-life computer models capturing how fear works in people and how it spreads through human societies. The best advice these models have to offer right now is that we need to think about the novel coronavirus as four separate epidemics: In addition to the disease it causes, Covid-19, there are also in epidemics of fear about the virus, fear about the economyand likely soonfear about a new vaccine. All four contagions are closely intertwined and will interact to amplify each other in complex ways.

To get the world back on track requires controlling all four horsemen of the Covid-19 apocalypsewhich makes the response far more complicated than leaders seem to appreciate.

It will involve overlapping and ongoing responses: continued distancing and testing of people for infection; rapid fielding of a new antibody test to determine immunity so people can go back to work safely; development of a safe, effective vaccine to keep Covid-19 at bay; andimportantlya persuasive information campaign, even before it arrives, against needless fears of vaccination. This combination offers the best chance of winning the long game against Covid-19.

Right now, and until we field a vaccine, theres no dispute that large-scale social distancing is the only tool we have to slow the immediate pandemic wave. However, it is important to recognize that distancing wont eradicate the diseaseand that premature lifting of distancing can bring the disease back with a vengeance.

We have seen this before. In the falls and springs of 1918 and 1919, during a devastating influenza pandemic, virtually every major city in the U.S. and many European ones as well experienced two distinct waves of the "Spanish flu," separated by just over four months. The second wave of the disease has long been a mystery. It is very unlikely that the second wave was a new viral strain, produced by mutation. Instead, its more likely that the wave was triggered by human behavior, and, in particular, by contagious fear.

To demonstrate how this could explain the second-wave phenomenon, in 2008, several colleagues and I published a computer model of how disease spreads in a population, which we called the coupled contagion model. It included two contagions: one of disease itself, and one of fear of the disease. As infection spreads, so does fear of it. This fear can actually be helpful: When people are afraid, they take urgent action like self-isolation and quarantines, which suppress the spread of infection. However, once the level of infection gets low, the fear evaporates and people come out of the basement: social distancing is lifted, quarantines end, schools and theaters reopen, transportation resumes. In a case like this, it is the decline of fear that wreaks havoc. If even a few infected cases are still at large, the resumption of business as usual simply pours gasolinein the form of susceptible peopleon to those infectious embers, and a second wave ignites.

In 1918, exactly this behavioral story unfolded in Chicago. When the disease flared in October, Health Commissioner John Dill Robertson declared to the public, If you have a cold and are coughing and sneezing go home and go to bed. Guidance like this suppressed the disease to very few cases by mid-November, at which point he wrote to the president of the Chicago Association of Commerce, We are practically out of the woods. All bans are off. He was right. They were practically out of the woods. But for pandemics, practically isnt good enough. The premature lifting of social distancing led to second waves in Chicago and other major cities here and abroad.

Fatiguing and costly as it will be, we must not repeat this mistake out of zeal to reopen the economy. Instead, we need to use what we knowfrom biology, from experience, and also from new tools to model human behaviorto guide our response. Heres where they point us now:

First, social distancing needs to continue. We simply dont have enough information to let down our guard yet.

Second, rapid development and wide distribution of a blood test to detect antibodies to the virus is essential. Unlike the current test, which tracks the disease itselfand is crucial in allocating emergency resources and detecting where the outbreak is subsidingthe antibody test will tell us whos had the disease and may therefore be immune to reinfection. Anthony Fauci, the governments top infectious-disease official, has expressed high confidence in this conferred immunity. As he put it, It's never 100 percent, but I'd be willing to bet anything that people who recover are really protected against reinfection."

The huge economic importance of antibody testing is that able-bodied people in this immune group could go back to work safely and also provide backup to heath care workers to meet surge Covid-19 demand. To help policymakers think about how to reopen the economy, weve recently done a calculation on this. Erez Hatna, Abbey M. Jones at New York University's School of Global Public Health and I estimate that at least 36 percent of all Americans who contract Covid-19 will fall into this immune able-bodied labor pool.

Fauci has recently estimated that between 100,000 and 200,000 Americans will die in the course of the pandemic. If you assume (very conservatively) that 2 percent of infected people will die, then to end up with 100,000 deaths, you must have 5,000,000 infected people. If, as we estimate, 36 percent of those can work, you get an immune labor force of 1.8 million. At Faucis higher figure of 200,000 deaths, you get a workforce of 3.6 million. Either way, here is a labor force to help restart the economy without restarting the pandemic and bridge the gap until we have a vaccine.

Third, well need to get ahead of the potential vaccine fear. Much hope is being placed in a Covid-19 vaccine, now being rushed into development, but still a year to 18 months away at the earliest. Once it exists, the power of contagious fear to shape an epidemics trajectory will likely show itself again. Given the steady growth of mistrust and misinformation surrounding vaccine safety in recent years, a Covid-19 vaccinedesigned, tested and fielded under tremendous time pressuresis likely to be greeted with suspicion by many. And that is especially so if the young and healthy are seen as shouldering the risks of vaccination to protect more vulnerable populations.

Even a safe and effective vaccine will do no good if people refuse to take it. The World Health Organization recently included vaccine refusal in the top 10 threats to global health. Fear-driven vaccine refusal is responsible for the resurgence of measles in the U.S. and Europe and even polio in many countries. We cannot rule out the possibility that vaccine refusal will undermine the worldwide effort to bring this new coronavirus to heel.

Recent experience gives us reason for concern. In 2009, even after the WHO had declared swine flu to be a pandemic, 50 percent of Americans refused the vaccine. If fear and suspicion drove a similar proportion of Americans to decline an effective Covid-19 vaccine, then, given our estimates of its ability to spread, the coronavirus transmission would likely stand right at the knife-edge between reignition and extinction. A third contagion, fear of the vaccine, could push us over the threshold into a renewed epidemic.

What do the models show? With Hatna at the NYU School of Global Public Health and Jennifer Crodelle of the Courant Institute of Mathematical Sciences at NYU, we have extended the coupled-contagion model discussed above, adding a third contagion, of vaccine fear. Everything turns on the relationship between the two fears, one of disease, the other of vaccine. In our model, if fear of disease exceeds fear of vaccine, then vaccine acceptance rises and the disease is suppressed. But if, at low disease prevalence, the fear of disease sinks below the fear of vaccine (as might happen when a disease recedes from our collective memory), people are more afraid of the vaccine than the disease. They eschew vaccine and a new disease cycle explodes.

This also rings true historically. Smallpox, one of the great scourges of human history, kills roughly 30 percent of those infected. Yet, even when inoculation (with cowpox) was discovered, cycles of vigilance and complacency kept smallpox alive. In her wonderful social history of smallpox, the Speckled Monster, Jennifer Carrell recounts, In London, inoculations popularity waxed and waned through the 1730s, with the force of the disease: in bad years, people flocked to be inoculated; in light years, the practice shrank. Inoculation was a securitythe only securityto cling to within the terror of an epidemic; in times of good health, however, it looked like a foolish flirtation with danger.

We cannot afford such cycles of vigilance and complacency toward Covid-19, particularly if it is with us to stay, as a seasonal presence like flu, or if it continues to find sanctuary between human outbreaks in the kinds of wild animals from which it jumped in Wuhan.

One of the most challenging random variables in all this has been President Donald Trump, who has been a powerful agent of fear. To understand why, and how public statements can do measurable damage, it helps to understand how our fear model reflects human behavior.

My own NYU lab specializes in agent-based modeling to figure out how real people respond to crises. Essentially, we build artificial societies of cognitively plausible software people who interact on computer-simulated landscapes to generate, or grow, all sorts of social and economic dynamics, including epidemics. Unlike the cool-headed rational actors of standard economics, my latest software person, dubbed Agent_Zero, has emotions, and notably a fear module, a set of equations capturing both the acquisition of fear given a threat and its extinction in the threats absence.

Recent advances in neuroscience provide the underpinning needed to endow our agents with such psychological depth. This field teaches us that the main driver of fear is surprisethe violation of expectations. In our Agent_Zero models, we have watched the power of surprise drive fear and generate contagions of collective behavior that range from counter-productive to disastrous.

Trumps initial stream of dismissive statements (Its going to disappear. One day, its like a miracle, it will disappear) did the same thing. They set us up for panic, including the financial panic he cares most about, by inflating expectations that were shattered by the truth.

After the baseless and false expectations Trump created, Americans responded with a surprise that rippled outward in predictable ways. Shock maximized the mutually amplifying fear spikes of disease and financial collapse, precisely when we should be controlling both.

Trump may never accept responsibility for the markets panicked response to Covid-19. But our modeling suggests that he played a pivotal role in creating it.

We cannot afford another round of false expectations whose inevitable failure will generate new cascades of counter-productive fear and disease. We must accept the epidemiological evidence and tell the truth to our level best. We must learn from history and stay the social distancing course, develop the antibody test and use it to put people back to work safely. Most importantly, we must understand and manage our intertwined fears, especially the prospect that fear of vaccine may subvert our epidemic control efforts down the road.

We cannot repeat the mistakes of 1918. Practically out of the woods wont work. In a world that is globally connected physically and informationallyand hence emotionallyif anyone is still in the woods, then we all are.

Continued here:
Are We Already Missing the Next Epidemic? - POLITICO

Warmer Spring Weather In Kansas City Might Slow COVID-19, But Don’t Expect It To Go Away – KCUR

Normally by April, most seasonal colds and flu have run their course, and allergies take over as the main culprit for causing coughs and sore throats.

COVID-19 might ease up slightly along with rising temperatures in the Kansas City area, but experts dont think the disease will turn out to be just a seasonal problem.

I think there may well be a seasonal component to it, but its also true that its not going to go away, in the sense that there wont be cases running around, says Gregory Glass, a researcher at the University of Floridas Emerging Pathogens Institute.

COVID-19 has only infected people for a few months, and some researchers initially thought that it might not spread as easily in warm and humid conditions because, while it surged in colder parts of Asia like China and South Korea, few cases had been identified in more tropical countries like Thailand or Vietnam.

Those predictions have turned out to be overly optimistic, as demonstrated by the large numbers of new cases in warm, humid places like Florida and Louisiana.

If people are really counting on this to control or protect themselves from disease, Glass says, its really not something I would want to hang my hat on.

Glass thinks the low case numbers in many tropical countries may be due to lack of testing.

He says that some viruses do seem to spread less easily in warmer weather, but researchers wont know much about how weather affects COVID-19 until we have lived with it for at least a full year.

But even if warmer temperatures and higher humidity dont reduce its spread, Glass says that there are things we know about how colds and flu spread that provide some cause for optimism.

He explains that, in fact, the flu and colds dont really disappear in the spring and summer. They only slow down, and thats due in part to human behavior.

Cold and flu viruses seem to spread less in the summer in part because school is typically out and people spend less time packed together in confined spaces than they do when its cold outside.

If people can manage to slow the spread of COVID-19 through social distancing in the coming weeks and months, they may, just by their own behavior, turn it into more of a seasonal virus.

Historically, the outbreak started in China in the winter, Glass says. If theyve really controlled for COVID-19 as well as theyve stated, the cases are going to go down, when? Leading into their summer. So youve immediately introduced a seasonality component.

Glass says that people in the U.S. could also greatly reduce COVID-19 by summer through social distancing, though he cautions that that warmer weather could have the opposite effect if it causes people to crowd together in parks and beaches.

Alex Smith is a health care reporter for KCUR. You can reach him at alexs@kcur.org.

Follow this link:
Warmer Spring Weather In Kansas City Might Slow COVID-19, But Don't Expect It To Go Away - KCUR